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Cystinuria is caused by the inherited defect of apical
membrane transport systems for cystine and dibasic amino
acids in renal proximal tubules. Mutations in either SLC7A9 or
SLC3A1 gene result in cystinuria. The mutations of SLC7A9
gene have been identified mainly from Italian, Libyan Jewish,
North American, and Spanish patients. In the present study,
we have analyzed cystinuria cases from oriental population
(mostly Japanese). Mutation analyses of SLC7A9 and SLC3A1
genes were performed on 41 cystinuria patients. The uptake
of 14C-labeled cystine in COS-7 cells was measured to
determine the functional properties of mutants. The protein
expression and localization were examined by Western blot
and confocal laser-scanning microscopy. Among 41 patients
analyzed, 35 were found to possess mutations in SLC7A9. The
most frequent one was a novel missense mutation P482L that
affects a residue near the C-terminus end of the protein and
causes severe loss of function. In MDCK II and HEK293 cells,
we found that P482L protein was expressed and sorted to the
plasma membrane as well as wild type. The alteration of
Pro482 with amino acids with bulky side chains reduced the
transport function of b0,þAT/BAT1. Interestingly, the
mutations of SLC7A9 for Japanese cystinuria patients are
different from those reported for European and American
population. The results of the present study contribute
toward understanding the distribution and frequency of
cystinuria-related mutations of SLC7A9.
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Cystinuria (MIM 220100) is an inherited disorder owing to
the defective transport of cystine and dibasic amino acids
across the epithelial cells of renal proximal tubule and small
intestine.1 The incidence of cystine crystalluria reported in
Western countries and in Japan varied from 15 000:1 to
50 000:1.2,3 The patients suffer from recurrent nephrolithiasis
leading to severe renal dysfunctions for which repeated
therapies are imperative.4 Classical cystinuria has been
classified into three types (I, II, and III) based on the
excretion of cystine and dibasic amino acids in obligate
heterozygotes.5 Type I heterozygotes show a normal amino-
acid urinary pattern, whereas type II and III heterozygotes
exhibit high or moderate levels of hyperexcretion of cystine
and dibasic amino acids.5 The discovery of a single-
membrane-spanning type II membrane glycoprotein rBAT
encoded by SLC3A16–10 and 12-membrane-spanning protein
b0,þAT/BAT1 encoded by SLC7A911–13 has brought a break-
through in the understanding of the molecular basis of
cystinuria and cystine transport in the renal proximal
tubules.
The analyses of cystinuria patients have revealed distinct
cystinuria-related mutations in SLC3A1 and SLC7A9
genes.14,15 It was originally supposed that mutations of
SLC3A1 and SLC7A9 genes are responsible for type I and
non-type I (type II and III) cystinuria, respectively. However,
recent developments in the genetics and physiology of
cystinuria have not supported such a traditional classifica-
tion.16–18 Although SLC3A1 is associated with the type I
urinary phenotype, SLC7A9 mutations were found in all
three subtypes.16,17 Therefore, a new cystinuria classification
based on molecular analysis and not on urinary amino-acid
excretion patterns has been proposed: type A, due to two
mutations of SLC3A1; type B, due to two mutations of
SLC7A9; and type AB, with one mutation on each of the
above-mentioned genes.17 For SLC7A9 gene, International
Cystinuria Consortium and Rozen and colleagues identified
cystinuria-related mutations mainly from Italian,
Libyan Jewish, North American, and Spanish patients
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and established the genotype–phenotype relation for
SLC7A9.12,16–18 In the present study, we have analyzed
cystinuria cases from oriental population (mostly Japanese)
and found that the mutations of SLC7A9 for Japanese
cystinuria patients are quite different from those reported for
European, North American, and Libyan Jewish. We report
here that the most frequent one is a novel missense mutation
affecting the C-terminus of the transporter protein (Tables 1
and 2).
RESULTS
Mutations of SLC7A9 and SLC3A1 found in cystinuria patients
We studied 41 cystinuria patients from 39 cystinuria families
potentially representing 78 independent cystinuria-related
alleles. They were subjected to the mutation analysis of
SLC7A9 gene by direct sequencing. The mutations of SLC7A9
gene found in the cystinuria patients are listed in Table 3.
They include one frameshift (1105delA) and one nonsense
mutation (W69stop) that produce early stop codons, and
seven changes affecting single amino-acid residues (V142A,
G195R, L223M, N227D, R333W, R333Q, and P482L).
Among them, V142A, L223M, N227D, R333Q, 1105delA,
and P482L were novel mutations found for the first
time in the present investigation, whereas three mutations
(W69stop, G195R, and R333W) were reported previously
for the European, North American, and Libyan Jewish
population.12,16,18 The amino-acid alterations except V142A
and L223M were not found in 50 normal subjects. V142A
and L223M were, in contrast, found in normal subjects
without cystinuria phenotype. V142A and L223M were found
in 23 and 19 alleles out of 50 normal subjects (100
independent alleles), respectively, suggesting that these
amino-acid alterations represent polymorphic variations
of SLC7A9.
The location of the SLC7A9 mutations is shown at the
corresponding amino-acid residues in the 12-transmembrane
(TM)-domain model of b0,þAT/BAT1 protein in Figure 1.
Five cystinuria-specific missense mutations were localized
within the putative TM domains 5 and 6 (G195R and
N227D), in the putative intracellular loop between TM8 and
TM9 (R333W and R333Q), or in the C-terminus (P482L).
The one single nucleotide deletion is localized to the portion
corresponding to the putative intracellular loops between
TM8 and TM9 (1105delA). Three mutations (G195R,
R333W, and R333Q) alter amino-acid residues that are
conserved for all the human members of the heterodimeric
amino-acid transporter family (Figure 1).
Among 41 cystinuria patients examined in the present
study, we found mutations of SLC3A1 in five cases. Two cases
without any alterations in SLC7A9 gene possessed mutations
for SLC3A1: one as a homozygote for the deletion of T at
nucleotide 1820; the other as a compound heterozygote for
V183A (T548C)/C673R (T2017C); nucleotide numbers refer
to GenBank accession no. NM_000341 for rBAT cDNA.19
Among four cases with only polymorphic changes (V142A
and/or L223M) in SLC7A9, two cases possessed mutations for
SLC3A1: one as a homozygote for the insertion of TA at
nucleotide 1898; the other as a compound heterozygote for
V183A (T548C)/L346P (T1037C). The other two cases with
only polymorphic changes in SLC7A9 did not possess
SLC3A1 mutations. SLC3A1 mutations were not found in
the cases with cystinuria-specific mutations of SLC7A9 except
one P482L homozygote that also possesses I445T (T1334C)
mutation in SLC3A1.
Functional analysis of SLC7A9 mutations
All the SLC7A9 mutations found in the present study were
examined for amino-acid transport activity. As shown in
Figure 2, the cystinuria-specific mutations such as W69stop,
G195R, N227D, R333Q, R333W, 1105delA, and P482L
exhibited remarkable decrease in cystine transport activity
compared with wild-type b0,þAT/BAT1. In contrast, V142A
and L223M, which were also found in normal subjects, did
not affect or only slightly decreased the cystine transport
activity compared with wild-type b0,þAT/BAT1 (Figure 2).
We also constructed V142A/L223M double mutant, which
contains both V142A and L223M alterations because they are
possibly located in the same allele. As shown in Figure 2, even
the double mutation for V142A and L223M did not severely
affect the functional activity.
Table 1 | Primers used for amplification of SLC7A9 exons and their direct sequencing
Sense primer Antisense primer Size of amplified fragment
Exon 2 50-GAGCTTGCACTTGCGTCTTG-30 50-AATCAAAGAGTACATCTTCTGCCG-30 299a
Exon 3 50-TGGCCTTCTGGGCTGGGTC-30 50-AAGAGGGATACTGGCAGGGT-30 307
Exon 4b 50-AGCCTCCGGTGGGAGGAAG-30 50-GAGTCCCCAGACACCCTCTG-30 388
Exon 5b 50-AAAGGAGACTCTCTCCAGGG-30 50-ATGCTTCCTTGGAGATGGGCT-30 292
Exon 6 50-CCATCTTTCCCGTGGAGATACA-30 50-CAAACCCCAGAAAGGAGAACTC-30 279
Exon 7 50-CCACTAGCAGGGCCATTCAC-30 50-CGGGAAGGGCATCATGGAATAC-30 316
Exon 8b 50-CTGAACGTGGGTCTCCGTG-30 50-ACCTCCAGTGCTGACACCTG-30 235
Exon 9 50-CTCTTGGAGGCCGAGAAAGAC-30 50-GGGTGTTATTGCTTTCGCCGC-30 214
Exon 10 50-TGGTCTGCACTCTGGTCAGC-30 50-GGCATCTGGGTCATTTGGAAG-3 236
Exon 11 50-CTTCTTCGGTCTTCTGTGAC-30 50-CTAGAAGGCATGCCCCTAGC-30 314
Exon 12 50-AGGGGGTACATGGAGTTCATAC-30 50-GTGACAGAGGTCTTGGAGTC-30 366
Exon 13 50-CAGGGTCTAGGTGACGCATC-30 50-TCAGCTGACTTGGCTACAAGAG-30 218
aThe size of the fragments amplified by PCR using sense and antisense primers described is indicated (bp).
bThe primers for exons 4, 5, and 8 are identical to those for reference International Cystinuria Consortium.12
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P482L mutation
Among 41 cystinuria patients examined, cystinuria-specific
mutations of SLC7A9 excluding apparently polymorphic
changes (V142A and L223M) were found in 35 cases
(Table 3). It is noted that 25 cases were P482L homozygotes
and six cases were heterozygotes involving P482L mutations.
Urinary excretion levels of cystine and basic amino acids in
the P482L homozygotes, compound heterozygotes involving
P482L mutations, and P482L obligate heterozygotes
who exhibited no cystinuria symptoms are provided in
Table 4. P482L homozygotes and compound heterozygotes
exhibited a high level of urinary excretion of cystine, lysine,
arginine, and ornithine, whereas P482L obligate heterozy-
gotes exhibited a significantly lower level of excretion of these
amino acids, which is still higher than the normal levels
(Table 4).
We further examined two family pedigrees with P482L
mutation (Figure 3). In Family 1, the proband 1-6 with a
clinical history of nephrolithiasis was homozygous for P482L
and showed a high level of excretion of cystine and dibasic
amino acids (Table 5). The heterozygotes 1-2 and 1-3 showed
a lower level of amino acid excretion (Table 5). The urinary
amino acid excretion of 1-1 and 1-5 without P482L mutation
was within the normal range. In Family 2, 2-3 and 2-5 were
homozygous for P482L, which showed a high level of urinary
amino acid excretion. Although 2-2 exhibited a relatively
high urinary excretion level for a heterozygote, she did not
have an episode of delivery or removal of cystine stones.
Protein characterization of b0,þAT/BAT1 mutants
We performed Western blot analyses using an antibody raised
against the C-terminus portion of human b0,þAT/BAT1 on
the crude membrane fractions prepared from COS-7 cells
coexpressing wild-type or mutant b0,þAT/BAT1 with rBAT.
The antibody recognized a 41 kDa protein for wild-type
b0,þAT/BAT1 in the Western blot (Figure 4a). The band
disappeared in the presence of antigen peptides in the
absorption experiment, confirming the specificity of im-
munoreactions (data not shown). As shown in Figure 4a, the
bands with the identical size were detected for G195R,
N227D, R333W, and R333Q mutants. The anti-C-terminus
antibody could not detect W69stop and 1105delA, which lack
the C-terminus portions. Furthermore, the antibody could
not detect P482L, which has a mutation in the C-terminus
region for which the antibody was generated (Figure 4a).
We further performed Western blot analyses using an anti-
myc antibody on the membrane fractions prepared from
COS-7 cells coexpressing myc-tagged wild-type or mutated
b0,þAT/BAT1 with rBAT. The anti-myc antibody recognized
the bands with identical size as those detected by the anti-
b0,þAT/BAT1 C-terminus antibody (Figure 4b). The rank
order of the relative band intensity of myc fusion proteins for
G195R, N227D, R333W, and R333Q mutants determined by
the anti-myc antibody was identical to that of G195R,
N227D, R333W, and R333Q detected by the anti-C-terminus
antibody. The anti-myc antibody did not detect the protein
products of W69stop (B7 kDa) and 1105delA (B38 kDa)
with a myc epitope on their N-termini. In contrast to the
anti-C-terminus antibody, the anti-myc antibody recognized
the P482L with a myc epitope on its N-terminus (myc-
P482L), indicating that myc-P482L is present almost in the
same amount as that for wild-type b0,þAT/BAT1 (Figure 4b).
Localization of wild-type and P482L proteins in polarized
MDCK II cells
In order to determine the subcellular localization of P482L
protein, we performed confocal fluorescence analysis on the
MDCK II cells expressing GFP-b0,þAT/BAT1 (GFP: green
fluorescent protein) alone or both myc-rBAT and GFP-
b0,þAT/BAT1 or GFP-P482L. For the coexpression experi-
ments, the cells positive for both GFP fluorescence and Alexa
Fluor fluorescence (myc-rBAT positive) were used for the
Table 2 | The mutagenic oligonucleotide primersa
SLC7A9 mutagenesis primers
W69stop 50-CCTGCCTCATCATAT(A)bGGCGGCTTGCGGGG-30
G195R 50-CATCATCATCATCAGC(A)GGCTGGTGCTCCTGGC-30
V142A 50-GTGCGCCCTTCTATG(C)GGGCTGCAAGCCTC-30
L223M 50-GGGAGCCATCAGC(A)TGGCGTTTTACAATGG-30
N227D 50-CCTGGCGTTTTAC(G)ATGGACTCTGGGCC-30
R333Q 50-CATTTACGTGGCGGGC(A)GGGAGGGTCACATG-30
R333W 50-CATTTACGTGGCGGGC(T)GGGAGGGTCACATG-30
1105delA 50-GGGTCACATGCTCAAA*GTGCTTTCTTAC-30
P482L 5-GGAAGTGGTCCCAC(T)GGAGGAAGACCC-3
Alanine mutagenesis primers
M477A 50-GCACCTTCAGATGCTA(GC)GGAAGTGGTCCCAC-30
E478A 50-CTTCAGATGCTAATGG(CC)GTGGTCCCACCGGA-30
V479A 50-CAGATGCTAATGGAAG(CG)GTCCCACCGGAGGA-30
V480A 50-ATGCTAATGGAAGTGG(C)CCCACCGGAGGAAGA-30
P481A 50-GCTAATGGAAGTGGTC(G)CACCGGAGGAAGACC-30
E483A 50-GAAGTGGTCCCACCGG(CT)GAAGACCCTGAGTA-30
E484A 50-GTGGTCCCACCGGAGG(C)AGACCCTGAGTAACA-30
D485A 50-GTCCCACCGGAGGAAG(C)CCCTGAGTAACAAGC-30
P486A 50-CCCACCGGAGGAAGAC(G)CTGAGTAACAAGCTC-30
E487A 50-CCGGAGGAAGACCCTG(C)GTAACAAGCTCCGTC-30,
Leucine mutagenesis primers
M477L 50-CTTCAGATGCTA(C)TGGAAGTGGTCCC-30
E478L 500-CGAATGCTAATG(CT)AGTGGTCCCACC-30
V479L 5-GATGCTAATGGAA(C)TGGTCCCACCGGAG-30
V480L 50-CTAATGGAAGTG(C)TCCCACCGGAGGA-30
P481L 50-ATGGAAGTGGTC(C)TACCGGAGGAAGAC-30
E483L 50-GTGGTCCCACCG(CT)GGAAGACCCTGAG-30
E484L 50-GGTCCCACCGGAG(CT)AGACCCTGAGTAAC-30
D485L 50-CCACCGGAGGAA(CT)CCCTGAGTAACA-30
P486L 50-CCAGTAGGAAGACC(T)TGAGTAACAAGCTC-30
E487L 50-GGAGGAAGACCCT(CT)GTAACAAGCTCC-30
P482X mutation primers
P482G 50-GGAAGTGGTGCCA(GG)GGAGGAAGACCCTG-30
P482A 50-GGAAGTGGTCCCA(G)CGGAGGAAGACCCTG-30
P482S 50-GGAAGTGGTCCCA(T)CGGAGGAAGACCCTG-30
P482V 50-GGAAGTGGTCCCA(GT)GGAGGAAGACCCTG-30
P482I 50-GGAAGTGGTCCCA(ATT)GAGGAAGACCCTG-30
P482M 50-GGAAGTGGTCCCA(AT)GGAGGAAGACCCTG-S1
P482F 50-GGAAGTGGTCCCA(TTC)GAGGAAGACCCTG-30
P482W 50-GGAAGTGGTCCCA(TG)GGAGGAAGACCCTG-30
aSense strand primers are shown.
bMutated nucleotides are shown in parentheses.
*One nucleotide has been deleted.
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analyses. As shown in Figure 5a, GFP-b0,þAT/BAT1 protein
was localized in the cytoplasm when expressed alone in
MDCK II cells. Coexpression of GFP-b0,þAT/BAT1 with
myc-rBAT resulted in the apical localization of GFP-b0,þAT/
BAT1 protein in the MDCK II cells (Figure 5b). Similarly,
GFP-P482L protein was also localized to the apical mem-
brane when coexpressed with myc-rBAT (Figure 5c).
The plasma membrane expression of b0,þAT/BAT1 and
P482L proteins was further confirmed by surface biotinyla-
tion analysis (Figure 5d). HEK293 cells were used in this
experiment for their higher efficiency in biotinylation
analysis, probably due to the higher expression of
the proteins. Consistent with the observation in COS-7
cells, myc-b0,þAT/BAT1 but not myc-P482L showed
Table 3 | Summary of b0,+AT/BATl mutations in cystinuria patients
Mutation type Status
Nucleotide
change Exon Protein domain
Urinary cystine
(nmol/mg Cr)
Number of
patients
P482L Homozygote C1533T 13 C-terminus 2065.87305.3a 25
P482L Heterozygote C1533T 13 C-terminus ND 3
P482L Compound heterozygote G671A 5 TM5
G195R C1533T 13 C-terminus 2103.5 1
P482L Compound heterozygote C1085T 10 IL4
R333W C1533T 13 C-terminus 2628.4 1
P482L Compound heterozygote G1086A 10 IL4
R333Q C1533T 13 C-terminus ND 1
R333Q Homozygote G1086A 10 IL4 ND 1
N227D Heterozygote A767G 6 TM6 ND 1
1105delAb Homozygote 1105delA 10 IL4 2118.0 1
W69stop Compound heterozygote G294A TM2
1105delAb 1105delA 3 IL4 ND 1
V142A Heterozygotec T513C 4 EL2
L223M C755A 6 TM6 ND 4
Total 39
aMean7s.e.m. (n=7).
b1105delA results in the frameshift after Val340.
cIt is not known whether V142A and L223M mutations of these patients are in the same alleles or not.
ND, urinary cystine level was not determined for these cases. Instead, urinary cystine excretion was confirmed by cyanide-nitroprusside test. Cystine stones were also
confirmed by infrared spectrophotometry.
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N227D
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R333Q
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Figure 1 | Schematic representation of the mutations found in
SLC7A9 gene of patients with cystinuria. Nine mutations in SLC7A9
gene found in 41 cystinuria patients are depicted at the corre-
sponding amino acid residues in the 12-TM-domain model of
b0,þAT/BAT1 protein.26 Seven mutations (W69stop, G195R, N227D,
R333W, R333Q, 1105delA, and P482L) were cystinuria-specific,
whereas two (V142A and L223M) were also found in the normal
subjects (see text). W69stop, G195R, and N227D are located within
the putative TM domains. R333Q, R333W, 1105delA, and P482L are
located in the proposed intracellular loops or in the C-terminus
intracellular domain. The mutations reported previously12,16,18 were
labeled with *.
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Figure 2 | Effects of SLC7A9 mutations on the cystine transport
activity. Wild-type b0,þAT/BAT1 and indicated mutants were
transiently expressed in COS-7 cells together with rBAT. The uptake of
[14C]L-cystine (100mM) mediated by the expressed proteins was
measured as described in ‘Materials and Methods’. All transport
values except those for V142A were significantly lower than those for
wild-type coexpressed with rBAT. The transport values for L223M and
V142A/L223M were higher than those for W69stop, G195R, N227D,
R333Q, R333W, 1105delA, or P482L. V142A/L223M is a mutant that
contains both V142A and L223M mutations. Asterisks indicate
statistical significance (*Po0.05; ***Po0.005, Student’s unpaired
t-test).
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[14C]L-cystine uptake when coexpressed with rBAT in
HEK293 cells (data not shown). As shown in Figure 5d,
myc-b0,þAT/BAT1 and myc-P482L proteins were detected at
the plasma membrane when coexpressed with rBAT. The
myc-b0,þAT/BAT1 and myc-P482L proteins were not detected
at plasma membrane when solely expressed (Figure 5d).
Effect of P482L mutation
In order to understand why P482L, a single amino acid
alteration at the C-terminus of the transporter protein,
resulted in the loss of transport function, we performed site-
directed mutagenesis analyses. For the series of mutants in
which residues between Met477 and Glu487 were syste-
matically changed to alanine, no remarkable decrease was
observed in the [14C]L-cystine transport activity compared
with wild-type b0,þAT/BAT1 (Figure 6a). It is notable that
the alteration of Pro482 to alanine did not affect the [14C]L-
cystine transport activity in contrast to the severe decrease in
the transport activity observed for P482L. We, then, changed
individual amino acid residues located between residues 477
and 487 to leucine (Figure 6b). We found that P481L, V479L,
M477L, E478L, and V480L, in addition to P482L, exhibited a
significant decease in the [14C]L-cystine transport activity
Table 4 | Urine amino acid levels in P482L homozygotes, compound heterozygotes, and obligate heterozygotes
n Cystine Lysine Arginine Ornithine
P482L/P482L Homozygotes 7 2065.87305.3a
(965.9–3056.6)b
8270.971185.3
(3866.8–11860.7)
3299.37349.9
(1729.3–4482.8)
2233.07383
(1032.1–4150.2)
R333W+P482L Compound heterozygotes 1 2628.4 8855.4 3407.1 1592.7
G195R+P482L Compound heterozygotes 1 2103.5 12911.5 6396.8 3744.5
P482L/+ Obligate heterozygotes 7 603.07174.7a, ** 2534.77623.5** 75.7713.8** 170.9762.0**
(56.3–1417.8)b (172.7–4781.8) (25.6–118.4) (18.2–354.5)
Normal range 20–150 50–1300 10–60 5–40
(nmol/mg creatinine)
aMean7s.e.m. (n=7).
bRange of amino acid excretion levels.
**Po0.01, versus homozygotes and compound heterozygotes (Mann–Whitney U-test).
Family 1 Family 2
2-21-1
1-31-2
1-4 1-5 1-6
2-3 2-4 2-5 2-6
2-7
2-1
Figure 3 | Pedigrees of Japanese cystinuria families with P482L
mutation. Two Japanese families (Families 1 and 2) with P482L
mutation examined are shown.
Table 5 | Urinary excretion levels of cystine and dibasic amino
acids of two family pedigrees
Individual
no.a Cystine Lysine Arginine Ornithine Sum
1-1 32.8 102.9 193.7 51.9 381.3
1-2 160.3 904.2 22.5 21 1108
1-3 791.1 3164.1 107.9 328.8 4391.9
1-4 385 2912.5 61.6 60.5 3419.6
1-5 64.7 222.8 23.1 20.1 330.7
1-6b 2240 7049 3538.3 2026.1 14853.4
2-1 255.6 1062.4 33.6 42.7 1394.3
2-2 1417.8 4012.9 100.3 354.5 5885.5
2-3 2932.6 9726.3 3440.7 2364.4 18464
2-4 ND ND ND ND ND
2-5b 1677.9 6370 2478.8 1692.7 12219.4
2-6 ND ND ND ND ND
2-7 891.7 4781.8 118.4 352.9 6144.8
Normal range 20–150 50–1300 10–60 5–40
(nmol/mg creatinine)
aThe individual numbers are corresponded to those of members of the family
pedigrees shown in Figure 4.
b1-6 and 2-5 are probands.
ND, Not determined.
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Figure 4 | Western blot analysis of b0,þAT/BAT1 and its mutants.
(a) b0,þAT/BAT1 and its mutants were transiently expressed in COS-7
cells with rBAT. The Western blot analysis using an anti-b0,þAT/BAT1
C-terminus antibody was performed on the membrane fraction
prepared from the COS-7 cells. The anti-b0,þAT/BAT1 C-terminus
antibody recognized a 41 kDa band for wild-type b0,þAT/BAT1 and
its mutants except W69stop, 1105delA, and P482L. (b) An anti-myc
antibody was used to detect b0,þAT/BAT1 and its mutants to which a
myc epitope was added at their N-termini. The myc-tagged proteins
were transiently expressed in COS-7 cells with rBAT. In the Western
blot, the anti-myc antibody recognized a 41 kDa band for wild-type
b0,þAT/BAT1 and its mutants including P482L.
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compared with wild-type b0,þAT/BAT1; however, the
magnitude of the decrease was much less than that for
P482L. In order to further investigate the effect of the
alteration of Pro482 to Leu, we constructed mutants in which
Pro482 is changed to various neutral amino acids with varied
bulkiness in their side chains. As shown in Figure 6c, the
alteration of Pro482 to amino acids with bulky side chains
such as leucine, isoleucine, methionine, phenylalanine, and
tryptophan severely decreased the [14C]L-cystine transport
activity, whereas the change to the amino acids with less-
bulky side chains such as glycine, alanine, serine, and valine
did not affect the functional activity.
DISCUSSION
In the present study, we examined cystinuria patients from
oriental population (40 Japanese and one Korean) and found
that mutations of SLC7A9 gene responsible for the disease of
the oriental population are quite different from those
reported previously for European, North American, and
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Figure 5 | Localization of P482L protein on the plasma
membrane. Shown are the x–z images of confocal laser-scanning
microscopic analyses on the MDCK II cells expressing (a) GFP-b0,þAT/
BAT1, (b) GFP-b0,þAT/BAT1 with rBAT, and (c) GFP-P482L with rBAT.
GFP-b0,þAT/BAT1 and GFP-P482L fusion proteins were sorted to the
apical membrane of the MDCK II cells when coexpressed with rBAT. In
contrast, GFP-b0,þAT/BAT1 fusion protein stayed in the cytoplasm
when solely expressed. AP and BL indicate apical and basal sites of
MDCK II cells, respectively. (d) Cell surface biotinylation analysis of
b0,þAT/BAT1 and P482L. HEK293 cells were transiently expressed
with myc-b0,þAT/BAT1 plus rBAT (lane 2), myc-P482L plus rBAT (lane
3), myc-b0,þAT/BAT1 alone (lane 4), or myc-P482L alone (lane 5).
Single bands of B41 kDa were observed for myc-b0,þAT/BAT1 and
myc-P482L coexpressed with rBAT (lane 2 and 3). Green: GFP
fluorescence; red: 4,6-diamidino-2-phenylindole fluorescence from
nuclei.
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Figure 6 | Effects of site-directed mutagenesis of C-terminus of
b0,þAT/BAT1 on [14C]L-cystine uptake. (a) The C-terminus amino
acids between residues 477 and 487 of b0,þAT/BAT1 were system-
atically mutated to alanine. The site-directed mutants exhibited no
remarkable decrease in the uptake of [14C]L-cystine compared with
that of wild type except for P482L mutation. (b) The C-terminus amino
acids between residues 477 and 487 of b0,þAT/BAT1 were system-
atically mutated to leucine. When Pro482 was changed to leucine, the
mutants expressed with rBAT exhibited remarkable decrease in the
uptake of [14C]L-cystine (100mM). (c) Pro482 of b0,þAT/BAT1 was
mutated to amino acids with varied bulkiness in their side chains. The
alteration of Pro482 to leucine, isoleucine, methionine, phenylalanine,
and tryptophan remarkably decreased the transport activity, whereas
the alteration to glycine, alanine, serine, and valine did not change the
transport activity. Asterisks indicate statistical significance (*Po0.05;
**Po0.01; ***Po0.005, Student’s unpaired t-test).
Kidney International (2006) 69, 1198–1206 1203
Y Shigeta et al.: A novel missense mutation of SLC7A9 o r i g i n a l a r t i c l e
Libyan Jewish.12,16,18 In contrast to W69Stop, G195R, and
R333W reported previously,12,16,18 N227D, R333Q, 1105delA,
and P482L found in the present study are novel cystinuria-
specific mutations, suggesting that these mutations are
unique to Japanese or Asian. It is noted that 31 out of 35
cases with cystinuria-specific mutations examined in the
present study involved P482L mutation, whereas this
mutation has not been reported for European, North
American, and Libyan Jewish population.12,16,18 It is, there-
fore, supposed that P482L mutation is prevailing in Japanese
and possibly in the other Asian population. G105R, the most
frequent mutation for European, North American, and
Libyan Jewish population (B25% of non-type I cystinuria
cases),18 was not found in the present study. It is interesting
that two cystinuria-specific missense mutations R333Q and
R333W found in the present study affect the same amino acid
residue, in which R333Q was only found for Japanese cases.
Arg333 is located in the putative intracellular loop between
TM domains 8 and 9 and conserved for human members of
heterodimeric amino acid transporter family.18 It is, thus,
proposed that this amino acid residue is critical in the
transport function or in the structural framework for the
light chains of heterodimeric amino acid transporters.
For P482L mutation most abundantly found in the
present study, we examined two family pedigrees and
confirmed Mendelian inheritance and phenotype–genotype
correlation (Figure 3 and Table 5). The homozygotes of this
mutation exhibited severe cystinuria phenotype with epi-
sodes of excretion or removal of renal stones and high level of
urinary excretion of cystine and dibasic amino acids.
Compared with normal individuals, P482L heterozygotes
exhibited a higher level of excretion of cystine and dibasic
amino acids into urine, consistent with the characteristics of
non-type I cystinuria (Table 5). Relatively large range of
variation in the amount of urinary excretion was observed
among heterozygotes (2-1, 2-2, and 2-7). This might be due
to the possible genetic alterations of b0,þAT/BAT1 or rBAT
that could not be detected in the present study, variations in
other factors related to the transporter systems, or differences
in diet and metabolism. We found three P482L heterozygotes
who suffer from nephrolithiasis. For these patients, no
mutation was found in the exons of SLC3A1 gene encoding
rBAT. Although we cannot exclude the involvement of
additional mutations of cis-regulatory elements of SLC7A9
gene and SLC3A1 gene or the mutations of unidentified genes
that might be essential for cystine transport, P482L hetero-
zygous mutation could possibly cause cystinuria symp-
toms dependent on the condition of the patients, which
has been reported for classic type II cystinuria with severe
phenotypes.16,20
P482L is the missense mutation affecting the C-terminus
of b0,þAT/BAT1. As shown in Figure 2, this mutation results
in the loss of function of b0,þAT/BAT1 protein coexpressed
with rBAT in COS-7 cells, indicating that Pro482 plays pivotal
role in the functional expression of the transporter. Loss of
function of P482L mutant is supposed not due to the loss of
protein expression or lack of ability to be sorted to the apical
membrane based on the following reasons: first, the anti-myc
antibody recognized the band for myc-tagged P482L with the
intensity similar to that of wild-type b0,þAT/BAT1 (Figure
4b); second, the GFP-tagged P482L protein was sorted to the
apical membrane when coexpressed with rBAT in MDCK II
cells similar to GFP-tagged wild-type b0,þAT/BAT1 (Figure
5b and c); finally, surface biotinylation study revealed that
P482L protein as well as wild-type b0,þAT/BAT1 protein was
detected at the plasma membrane upon coexpression with
rBAT in HEK293 cells (Figure 5d). In Figure 4b, the protein
products of W69stop and del1105A were not detected. This
might be due to the rapid degradation of the immature
proteins. A recent study on the crystal structure of Escherichia
coli 12-membrane-spanning transporters indicated that the
substrate binding sites are located in the hydrophilic pocket
surrounded by TM helices, suggesting that their N- and C-
terminal intracellular domains are not directly involved in the
substrate binding and translocation of substrates.21,22 Mam-
malian 12-membrane-spanning transporters phylogenetically
related to the bacterial 12-membrane-spanning transporters
are supposed to possess the analogous structure and operate
based on the similar structural trait.23 In order to examine
the roles of Pro482 in the C-terminus intracellular domain of
b0,þAT/BAT1, we performed site-directed mutagenesis
analyses. In the first series of experiments, C-terminus
amino-acid residues between Met477 and Glu487 were
systematically changed to alanine. Surprisingly, no remark-
able decrease was observed in the cystine transport activity
even when Pro482 was changed to alanine in spite of the
severe decrease in the function for Pro482-to-Leu alteration.
This indicates that Pro482 itself is not essential for the
function of b0,þAT/BAT1 protein but the incorporation of
leucine residue at position 482 interferes with the functional
expression.
We, thus, generated additional site-directed mutants in
which Pro482 was changed to various neutral amino acids. As
shown in Figure 6, the alteration of Pro482 to amino acids
with bulky side chains affected the function of b0,þAT/BAT1,
whereas the changes to residues with less bulky side chains
did not reduce the functional activity. It is, thus, suggested
that the bulky side chains incorporated at the C-terminus of
b0,þAT/BAT1 interfered with the functional expression of
b0,þAT/BAT1. By examining the site-directed mutants in
which residues between Met477 and Glu487 were system-
atically changed to leucine, it was found that leucine
alteration affected the function of b0,þAT/BAT1 only when
quite restricted residues were changed to leucine. Based on
these observations, we, thus, propose that the bulky side
chain incorporated at the position 482 of b0,þAT/BAT1
somehow suppressed the transport function possibly by
interfering with intra- or intermolecular interactions. The
further investigation would lead to the understanding of the
novel regulatory mechanisms of heterodimeric amino acid
transporters as well as the role of P482L mutation in the
pathogenesis of cystinuria.
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In the present study, we have identified several novel
mutations of SLC7A9 from oriental population and found
that mutations are quite different from those reported
previously for European, North American, and Libyan
Jewish. Our results contribute toward understanding the
distribution and frequencies of cystinuria-related mutations
of SLC7A9.
MATERIALS AND METHODS
Subjects
Forty-one cystinuria patients (40 Japanese and one Korean) from 39
independent families were studied. All had an episode of delivery or
removal of cystine stones. Urinary excretion of cystine and dibasic
amino acids was determined in 24 h urine samples by quantitative
ion-exchange chromatography or reverse-phase high-performance
liquid chromatography. The amino acid content was corrected per
gram of creatinine. In all patients whose urinary cystine excretion
was analyzed quantitatively, cystine excretion was over 800 nmol/mg
creatinine. Urinary hyperexcretion of dibasic amino acids was also
confirmed. The urinary excretion of other neutral amino acids was
within normal ranges for all patients. For the patients whose urinary
amino acid levels were not quantitatively analyzed, the urinary
cystine excretion was confirmed by cyanide-nitroprusside test and
their cystine stones were analyzed by infrared spectrophotometry.3
Genomic DNA was obtained from the patients and the members of
the selected family pedigrees. Genomic DNA was also obtained from
50 unrelated normal individuals who served as controls. The study
protocol was approved by the Institutional Research Boards of Chiba
University Graduate School of Medicine and of Kyorin University
School of Medicine. All study subjects gave written informed
consent, and the ethics committee of Chiba University Graduate
School of Medicine and of Kyorin University School of Medicine
gave permission for the analyses in relation to cystinuria.
Determination of exon–intron boundaries of SLC7A9
The location and sequence of all exon–intron boundaries were
determined by direct sequencing of the products obtained by PCR
amplification of genomic DNA with randomly designed cDNA-
derived oligonucleotide primers, using an ABI PRISM Sequencer
(Perkin Elmer, Wellesley, MA, USA). SLC7A9 consisted of 13 exons.
The codon for the translation-initiator methionine (ATG) was
located in exon 2, whereas the termination codon TAA was located in
exon 13. The exon–intron boundaries we determined have turned out
to be identical to those obtained by deducing the recently released
genomic DNA sequence of SLC7A9 (accession no. AC008805).18
Mutation analysis and direct sequencing
Genomic DNA was extracted from whole blood using the Wizard
Genomic DNA Purification Kit (Promega, Madison, WI, USA).
Twelve pairs of oligonucleotide primers (Table 1) were synthesized
in order to amplify all exons of SLC7A9 gene by PCR for direct
sequencing. In all cases, sequencing of both strands of the PCR
products was performed.24 Mutation analysis of SLC3A1 gene was
performed for the above-described 41 cystinuria patients using
oligonucleotide primers as described elsewhere.25
Construction of mutant cDNAs
All cDNA mutants were constructed by using the QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according
to the manufacturer’s instructions. The mutagenic oligonucleotide
primers are shown in Table 2. Proper construction of the mutated
cDNAs was confirmed by complete sequencing.
Functional expression in COS-7 cells
cDNAs for human rBAT and those for wild-type or mutated human
b0,þAT/BAT1 in pcDNA3.1(þ ) were expressed transiently in COS-
7 cells using LipofectAMINETM2000 (Invitrogen, Carlsbad, CA, USA)
following the manufacturer’s instructions.26 For co-transfection,
10 mg of cDNA for b0,þAT/BAT1 or its mutants and 10 mg of rBAT
cDNA were diluted into 1 ml of opti-MEM reduced-serum medium
(Invitrogen, Carlsbad, CA, USA) and mixed with 60 ml LF2000
reagent diluted in 1 ml opti-MEM reduced-serum medium. After
incubation for 20 min at room temperature, the mixture was applied
to COS-7 cells maintained in a tissue culture dish (90 mm diameter)
with 70–90% confluence. At 24 h after transfection, the transfected
cells were collected and seeded on a 24-well plate (2 105 cells/well)
in fresh medium. Amino acid uptake measurements were performed
at 48 h after transfection of the plasmids as described elsewhere.26
Anti-human b0,þAT/BAT1 antibodies
Oligopeptides (QMLMEVVPPEEDPEC) corresponding to amino
acid residues 474–487 of human b0,þAT/BAT1 were synthesized.
Anti-peptide antibody was produced as described elsewhere.27,28
Construction of the fusion proteins
The fusion proteins in which myc and GFP epitopes were fused to
the N-terminus of wild-type and mutant b0,þAT/BAT1 were
generated. The coding regions of cDNAs for the wild-type and
mutant b0,þAT/BAT1 were amplified by PCR using primers
containing restriction enzyme cleavage sites for HindIII, XhoI,
EcoRI, or KpnI. After digestion with HindIII and XhoI or EcoRI and
KpnI, the fragments were ligated with pCMV-Taq3 vector (Strata-
gene, La Jolla, CA, USA) digested with HindIII and XhoI or pEGFP
C2 vector (Clontech, Mountain View, CA, USA) digested with EcoRI
and KpnI, respectively. Proper construction was confirmed by DNA
sequencing.
Western blotting
COS-7 cells were co-transfected with cDNAs for human rBAT and
those for wild-type, mutated human b0,þAT/BAT1 or their myc-
tagged products as described above. At 48 h after transfection, the
transfected cells were collected and homogenized as described
elsewhere.29 The anti-human b0,þAT/BAT1 (1:2000) antibody or
anti-myc (1:2000) antibody (Invitrogen, Carlsbad, CA, USA) was used
as the primary antibody. To verify the specificity of immunoreactions
by absorption experiments, the membranes were treated with primary
antibodies in the presence of antigen peptides (50mg/ml).29
Confocal laser-scanning microscopy
MDCK II cells provided by Dr Dietrich Keppler (European
Molecular Biology Laboratory, Heidelberg, Germany) were cultured
as described.30 For localization of b0,þAT/BAT1 and P482L mutant
protein, MDCK II cells were grown on transwell membranes
(membrane diameter 24 mm, pore size 3.0 mm; Costar, Corning,
NY, USA) for 1 week (100% confluence) and then co-transfected
with cDNAs for myc-tagged human rBAT (1mg) and those for GFP-
tagged wild-type human b0,þAT/BAT1 or GFP-P482L (1mg) using
LipofectAMINETM2000. Cells were fixed with 4% paraformaldehyde
in phosphate-buffered saline and permeabilized with 0.5% Triton
X-100 in phosphate-buffered saline containing 5% goat serum.
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Membranes were incubated with an anti-myc (1:500) antibody
(Invitrogen, Carlsbad, CA, USA) at room temperature for 1 h. After
three washes with phosphate-buffered saline, the membranes were
incubated with Alexa Fluor 546 goat anti-mouse IgG (Molecular
Probes, Eugene, OR, USA) as a secondary antibody for 1 h. Argon
and HeNe laser beams were used for excitation at 488 nm for GFP
and 543 nm for Alexa Fluor 546 visualization, respectively. Nuclei
were stained with 4,6-diamidino-2-phenylindole nucleic acid stain-
ing for 10 min and visualized by excitation at 405 nm with Diode 405
laser. Images were acquired using Carl Zeiss LSM510 META laser-
scanning confocal microscope (Carl Zeiss, Frankfurt, Germany).
Cell surface biotinylation
Surface biotinylation of b0,þAT/BAT1 and P482L mutant at the
plasma membrane of HEK293 cells was performed as describe
elsewhere.31,32 myc-tagged b0,þAT/BAT1 and myc-P482L were
detected with an anti-myc (1:2000) antibody (Invitrogen) and
horseradish peroxidase-conjugated anti-mouse IgG as a secondary
antibody (Jackson ImmunoResearch, West Grove, PA, USA).
Statistical analysis
Data are expressed as mean7s.e.m. Statistical differences were
determined using Student’s unpaired t-test. Mann–Whitney U-test
was used to analyze urinary amino-acid levels among different
genotypes. Differences were considered significant at the level of
Po0.05.
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